These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 24648158

  • 21. Myotoxicity studies of injectable biodegradable in-situ forming drug delivery systems.
    Kranz H, Brazeau GA, Napaporn J, Martin RL, Millard W, Bodmeier R.
    Int J Pharm; 2001 Jan 05; 212(1):11-8. PubMed ID: 11165816
    [Abstract] [Full Text] [Related]

  • 22. Asenapine maleate in situ forming biodegradable implant: an approach to enhance bioavailability.
    Avachat AM, Kapure SS.
    Int J Pharm; 2014 Dec 30; 477(1-2):64-72. PubMed ID: 25305379
    [Abstract] [Full Text] [Related]

  • 23. Noninvasive characterization of the effect of varying PLGA molecular weight blends on in situ forming implant behavior using ultrasound imaging.
    Solorio L, Olear AM, Hamilton JI, Patel RB, Beiswenger AC, Wallace JE, Zhou H, Exner AA.
    Theranostics; 2012 Dec 30; 2(11):1064-77. PubMed ID: 23227123
    [Abstract] [Full Text] [Related]

  • 24. Influence of the microencapsulation method and peptide loading on poly(lactic acid) and poly(lactic-co-glycolic acid) degradation during in vitro testing.
    Witschi C, Doelker E.
    J Control Release; 1998 Feb 12; 51(2-3):327-41. PubMed ID: 9685930
    [Abstract] [Full Text] [Related]

  • 25. In situ forming implants for the delivery of metronidazole to periodontal pockets: formulation and drug release studies.
    Kilicarslan M, Koerber M, Bodmeier R.
    Drug Dev Ind Pharm; 2014 May 12; 40(5):619-24. PubMed ID: 24369747
    [Abstract] [Full Text] [Related]

  • 26. An in vitro gel-based system for characterizing and predicting the long-term performance of PLGA in situ forming implants.
    Li Z, Mu H, Weng Larsen S, Jensen H, Østergaard J.
    Int J Pharm; 2021 Nov 20; 609():121183. PubMed ID: 34653562
    [Abstract] [Full Text] [Related]

  • 27. In-situ forming PLGA implants for intraocular dexamethasone delivery.
    Bode C, Kranz H, Siepmann F, Siepmann J.
    Int J Pharm; 2018 Sep 05; 548(1):337-348. PubMed ID: 29981408
    [Abstract] [Full Text] [Related]

  • 28. Design of a long-term antipsychotic in situ forming implant and its release control method and mechanism.
    Wang L, Wang A, Zhao X, Liu X, Wang D, Sun F, Li Y.
    Int J Pharm; 2012 May 10; 427(2):284-92. PubMed ID: 22387369
    [Abstract] [Full Text] [Related]

  • 29. Improved small molecule drug release from in situ forming poly(lactic-co-glycolic acid) scaffolds incorporating poly(β-amino ester) and hydroxyapatite microparticles.
    Fisher PD, Palomino P, Milbrandt TA, Hilt JZ, Puleo DA.
    J Biomater Sci Polym Ed; 2014 May 10; 25(11):1174-93. PubMed ID: 24903524
    [Abstract] [Full Text] [Related]

  • 30. Myotoxicity studies of O/W-in situ forming microparticle systems.
    Rungseevijitprapa W, Brazeau GA, Simkins JW, Bodmeier R.
    Eur J Pharm Biopharm; 2008 May 10; 69(1):126-33. PubMed ID: 18036794
    [Abstract] [Full Text] [Related]

  • 31. Development of an in situ forming PLGA drug delivery system I. Characterization of a non-aqueous protein precipitation.
    Körber M, Bodmeier R.
    Eur J Pharm Sci; 2008 Nov 15; 35(4):283-92. PubMed ID: 18721875
    [Abstract] [Full Text] [Related]

  • 32. Enhanced encapsulation and bioavailability of breviscapine in PLGA microparticles by nanocrystal and water-soluble polymer template techniques.
    Wang H, Zhang G, Ma X, Liu Y, Feng J, Park K, Wang W.
    Eur J Pharm Biopharm; 2017 Jun 15; 115():177-185. PubMed ID: 28263795
    [Abstract] [Full Text] [Related]

  • 33. In situ forming phase-inversion implants for sustained ocular delivery of triamcinolone acetonide.
    Sheshala R, Hong GC, Yee WP, Meka VS, Thakur RRS.
    Drug Deliv Transl Res; 2019 Apr 15; 9(2):534-542. PubMed ID: 29484530
    [Abstract] [Full Text] [Related]

  • 34. Design of physostigmine-loaded polymeric microparticles for pretreatment against exposure to organophosphate agents.
    Chaw CS, Tan CW, Yang YY, Wang L, Moochhala S.
    Biomaterials; 2003 Mar 15; 24(7):1271-7. PubMed ID: 12527268
    [Abstract] [Full Text] [Related]

  • 35. Sustained release of etanidazole from spray dried microspheres prepared by non-halogenated solvents.
    Wang FJ, Wang CH.
    J Control Release; 2002 Jun 17; 81(3):263-80. PubMed ID: 12044566
    [Abstract] [Full Text] [Related]

  • 36. A novel risperidone-loaded SAIB-PLGA mixture matrix depot with a reduced burst release: effects of solvents and PLGA on drug release behaviors in vitro/in vivo.
    Lin X, Yang S, Gou J, Zhao M, Zhang Y, Qi N, He H, Cai C, Tang X, Guo P.
    J Mater Sci Mater Med; 2012 Feb 17; 23(2):443-55. PubMed ID: 22170300
    [Abstract] [Full Text] [Related]

  • 37. Investigation of the bioequivalence of montelukast chewable tablets after a single oral administration using a validated LC-MS/MS method.
    Zaid AN, Abualhasan MN, Watson DG, Mousa A, Ghazal N, Bustami R.
    Drug Des Devel Ther; 2015 Feb 17; 9():5315-21. PubMed ID: 26451086
    [Abstract] [Full Text] [Related]

  • 38. Analysis of initial burst in PLGA microparticles.
    Allison SD.
    Expert Opin Drug Deliv; 2008 Jun 17; 5(6):615-28. PubMed ID: 18532918
    [Abstract] [Full Text] [Related]

  • 39. Development of depot PLGA-based in-situ implant of Linagliptin: Sustained release and glycemic control.
    Gomaa E, Eissa NG, Ibrahim TM, El-Bassossy HM, El-Nahas HM, Ayoub MM.
    Saudi Pharm J; 2023 Apr 17; 31(4):499-509. PubMed ID: 37063437
    [Abstract] [Full Text] [Related]

  • 40. Aerosolizable modified-release particles of montelukast improve retention and availability of the drug in the lungs.
    Patel B, Rashid J, Ahsan F.
    Eur J Pharm Sci; 2017 Jan 01; 96():560-570. PubMed ID: 27989858
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.